[go: up one dir, main page]

ATE401315T1 - 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel - Google Patents

5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel

Info

Publication number
ATE401315T1
ATE401315T1 AT00126672T AT00126672T ATE401315T1 AT E401315 T1 ATE401315 T1 AT E401315T1 AT 00126672 T AT00126672 T AT 00126672T AT 00126672 T AT00126672 T AT 00126672T AT E401315 T1 ATE401315 T1 AT E401315T1
Authority
AT
Austria
Prior art keywords
stands
optionally substituted
benzoxazepine
group
dialkoxyphenyl
Prior art date
Application number
AT00126672T
Other languages
English (en)
Inventor
Hidefumi Yukimasa
Yasuo Sugiyama
Ryuichi Tozawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE401315T1 publication Critical patent/ATE401315T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT00126672T 1995-09-13 1996-09-12 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel ATE401315T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23545795 1995-09-13

Publications (1)

Publication Number Publication Date
ATE401315T1 true ATE401315T1 (de) 2008-08-15

Family

ID=16986391

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96930365T ATE202774T1 (de) 1995-09-13 1996-09-12 Benzoxazepinverbindungen, ihre herstellung und verwendung als lipidsenker
AT00126672T ATE401315T1 (de) 1995-09-13 1996-09-12 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96930365T ATE202774T1 (de) 1995-09-13 1996-09-12 Benzoxazepinverbindungen, ihre herstellung und verwendung als lipidsenker

Country Status (8)

Country Link
US (5) US6110909A (de)
EP (1) EP1097928B1 (de)
AT (2) ATE202774T1 (de)
CA (1) CA2231052C (de)
DE (2) DE69637603D1 (de)
DK (1) DK0862562T3 (de)
ES (1) ES2158344T3 (de)
PT (1) PT862562E (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1097928B1 (de) * 1995-09-13 2008-07-16 Takeda Pharmaceutical Company Limited 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische Mittel
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
WO2002038180A1 (fr) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. Agent haute densite faisant monter le taux de lipoproteine-cholesterol
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1365745A2 (de) 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilisierte pharmazeutische und schilddrüsenhormon-zusammensetzungen und herstellungsverfahren
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US20020193440A1 (en) * 2001-02-20 2002-12-19 Ritter Steven C. Liothyronine sodium and levothyroxine sodium combination
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030175337A1 (en) * 2001-10-29 2003-09-18 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
CA2569686A1 (en) * 2004-06-11 2005-12-22 Takeda Pharmaceutical Company Limited Highly selective novel amidation method
EP1888562B1 (de) 2005-04-22 2014-06-18 Alantos Pharmaceuticals Holding, Inc. Dipeptidylpeptidase-iv-hemmer
US20090088416A1 (en) * 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
GB202214609D0 (en) 2022-10-04 2022-11-16 Francis Crick Institute Ltd Methods of treatment of intestinal infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0567026A (ja) 1991-09-10 1993-03-19 Shikoku Nippon Denki Software Kk 周辺装置制御装置
US5726306A (en) * 1992-04-20 1998-03-10 Takeda Chemical Industries, Ltd. 4,1-benzoxazepin derivatives and their use
SG48855A1 (en) * 1992-04-20 1998-05-18 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
JP3128972B2 (ja) 1992-07-24 2001-01-29 ソニー株式会社 電子モジュールの製造方法
JPH075607A (ja) 1993-06-15 1995-01-10 Konica Corp ハロゲン化銀写真感光材料
JPH0710725A (ja) 1993-06-28 1995-01-13 Mitsui Toatsu Chem Inc シャンプー組成物
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
AU1589895A (en) * 1994-02-09 1995-08-29 Takeda Chemical Industries Ltd. Optically active 4,1-benzoxazepine derivatives useful as squalene synthase inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
CA2161849A1 (en) * 1994-11-01 1996-05-02 Kazuo Nakahama Production of optically active compounds
EP1097928B1 (de) * 1995-09-13 2008-07-16 Takeda Pharmaceutical Company Limited 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische Mittel
AU2401697A (en) * 1996-06-20 1998-01-07 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5886979A (en) * 1996-10-21 1999-03-23 Fujitsu Limitd Information recording medium and method for recording and reproducing information to a medium to prevent unauthorized copying
WO2002038180A1 (fr) * 2000-11-09 2002-05-16 Takeda Chemical Industries, Ltd. Agent haute densite faisant monter le taux de lipoproteine-cholesterol
WO2003002147A1 (fr) * 2001-06-28 2003-01-09 Takeda Chemical Industries, Ltd. Medicaments destines a la prevention/au traitement de troubles fonctionnels des organes et du dysfonctionnement des organes

Also Published As

Publication number Publication date
US6110909A (en) 2000-08-29
US6613761B1 (en) 2003-09-02
US20080153801A1 (en) 2008-06-26
DE69637603D1 (de) 2008-08-28
ATE202774T1 (de) 2001-07-15
EP1097928A1 (de) 2001-05-09
ES2158344T3 (es) 2001-09-01
EP1097928B1 (de) 2008-07-16
PT862562E (pt) 2001-11-30
US20070117787A1 (en) 2007-05-24
CA2231052C (en) 2007-11-13
DK0862562T3 (da) 2001-09-24
CA2231052A1 (en) 1997-03-20
DE69613710T2 (de) 2001-11-08
DE69613710D1 (de) 2001-08-09
US20040072819A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
ATE401315T1 (de) 5-(2,3-dialkoxyphenyl)-4,1-benzoxazepin-2-one als anti-hyperlipidämische mittel
ATE243697T1 (de) Substitutierte heterozyclische derivate als crf antagonisten
ATE215530T1 (de) 7-substituierte-8-substituierte-9-substituierte amino-7-demethyl-6-deoxy-tetracycline als antibiotische mittel
NZ237565A (en) Substituted thiazolidinones, oxazolidinones or imidazolidinones and antiinflammatory pharmaceutical compositions thereof
DE69626218D1 (de) 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinon derivate, deren herstellung und deren verwendung als antibakterielle mittel
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
PT918776E (pt) Sintese total de acilfulvenos antitumorais
DK1036074T3 (da) S-Oxid-tetrahydrothiopyran-phenyloxazolidinoner
ES2136887T3 (es) Derivados antifungicos de sordaridina.
ES2078876A1 (es) Una composicion herbicida a base de fenilpirazol 3-sustituidos.
DE69615694D1 (de) Triazole als fungizide mittel.
DK1021421T3 (da) Amino- og hydroxy-substituerede triphenyl-S-triaziner som stabilisatorer
WO1996005182A3 (de) Saccharinderivate
HU9501466D0 (en) Glycopyranoside benzothiophenes
ATE235450T1 (de) 2-indanmethanolderivate und ihre verwendung als riechstoffe
GB9811050D0 (en) Pyrazoles
DE69217148D1 (de) Isoxazole derivate als lichtschutzmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties